The findings of the current study reinforce the need for early treatment, suggesting that prenatal changes occurring during CNS development need to be targeted to address neurodevelopmental comorbidities in SMA while providing important proof of principle that transplacental in utero SMN replacement can reverse neurodevelopmental SMA phenotypes. Here, SMN2 is linked to proximal spinal muscular atrophy.